PhilipBreitfeldMD

Managing Director, The Breitfeld Group, LLC

Dr. Breitfeld is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1982 - 1985
University of RochesterResidency, Pediatrics, 1979 - 1982
University of Rochester School of Medicine and DentistryClass of 1979
Princeton UniversityAB, Chemistry, 1971 - 1975

PubMed

24 citations
Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group
Leo Mascarenhas, Elizabeth R. Lyden, Philip P. Breitfeld, David O. Walterhouse, Sarah S. Donaldson
Cancer. 2019-08-01
67 citations
Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review
Denis Leonardo Fontes Jardim, Eric S. Groves, Philip P. Breitfeld, Razelle Kurzrock
Cancer Treatment Reviews. 2017-01-01
73 citations
Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the C...
Leo Mascarenhas, Elizabeth Lyden, Philip P. Breitfeld, David O. Walterhouse, Sarah S. Donaldson
Journal of Clinical Oncology. 2010-10-20

Fannin/Allterum Awarded $2 Million SBIR Phase II Grant from NIH to Advance Monoclonal Antibody for Treating Childhood LeukemiaMay 8th, 2023
Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior LeadershipNovember 29th, 2016